US4407803A - Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives - Google Patents
Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives Download PDFInfo
- Publication number
- US4407803A US4407803A US06/293,767 US29376781A US4407803A US 4407803 A US4407803 A US 4407803A US 29376781 A US29376781 A US 29376781A US 4407803 A US4407803 A US 4407803A
- Authority
- US
- United States
- Prior art keywords
- hydrogen
- amino
- pyrazolinyl
- chloro
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention provides compositions for the treatment of rheumatoid arthritis, type III hypersensitivity diseases, diseases in which polymorphonuclear leukocyte accumulation contributes to the pathology, and other inflammatory conditions.
- An anti-inflammatory composition in dosage unit form is described.
- the present invention is directed to compounds of the formula ##STR5## wherein R 2 -R 8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR6## with the proviso that at least one but no more than one of the substituents R 2 -R 8 is ##STR7## and with the further provisos that at least four of the substituents R 2 -R 8 are hydrogen and R 2 cannot be ##STR8## when R 3 -R 8 are hydrogen, and pharmaceutically acceptable salts thereof.
- loweralkyl and “alkyl” as used herein refer to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, 2-methylhexyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
- halo refers to chloro, bromo, fluoro and iodo.
- the compounds described in this invention are prepared by the reaction of the appropriate hydrazine quinolines with acrylonitrile in the presence of a base such as sodium methoxide, sodium ethoxide or sodium hydroxide, in a protic solvent such as a lower alcohol at a temperature of from about 50°-200° C.
- a base such as sodium methoxide, sodium ethoxide or sodium hydroxide
- a protic solvent such as a lower alcohol
- the reaction can also be carried out without any solvent at elevated temperatures of from about 50°-150° C. in the presence of an ammonium quatenary salt such as choline.
- salts includes nontoxic acid addition salts of the compounds of the invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid.
- Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and like salts.
- metallic salts such as the sodium or potassium salt of the acid.
- the present compounds may be administered to warm-blooded animals orally or parenterally. They can generally be administered with a pharmaceutical carrier.
- pharmaceutical carrier for the purpose of the present invention, is intended to refer to any medium that is suitable for the preparation of a dosage unit form, and thus includes the tablet medium or a pharmaceutically acceptable vehicle or solvent such as is ordinarily used in the preparation of intravenous or intramuscular solutions.
- a pharmaceutical composition containing the compound can be administered to warm-blooded animals in parenteral or oral dosage form.
- amounts of from about 0.1 to 200 mg./kg. per day per patient are useful, with the total dose of up to 0.5 to 5.0 gm. per day being a suitable range for large animals, including humans.
- the above exemplified compounds can be placed in capsules, formulated into pills, wafers or tablets in conventional fashion together with pharmaceutical carriers well known in the art. Tablets may be prepared for immediate release of the active compound or they may be made enteric, i.e., whereby the active ingredient is released slowly over a period of several hours from within the intestinal tract.
- the compounds of the present invention have anti-inflammatory activity and inhibitory effect against Type III hypersensitivity reaction. These compounds are useful for the therapy of rheumatoid arthritis, other inflammatory conditions, Type III hypersensitivity diseases and in diseases in which polymorphonuclear leukocytes accumulation contributes to the pathology.
- the anti-inflammatory activity of these compounds was established by using a modification of the carrageenin pleurisy assay described by Vinegar et al. Proc. Soc. Exp. Biol. Med. 143:711 (1973). Table I shows the reduction in accumulation of exudate volume and leukocytes.
- the Arthus reaction represents one of the oldest and best studied models of immunological injury. It is produced by the injection of antigen locally into a hyperimmunized animal or by the injection of a small amount of antibody into the skin of an animal that has just previously been given a large amount of soluble antigen intravenously. In both cases the antigen and antibody become deposited in the walls of small venules. Plasma complement is rapidly bound and activated. Within a few hours neutrophils (PMNs) accumulate resulting in disruption of the basement membrane of vessel walls and marked edema and hemorrage in the surrounding tissue.
- PMNs neutrophils
- the reserve passive Arthus reaction test in rats is conducted as follows: Male Sprague-Dawley rats weighing approximately 130-160 g. are used, 4 rats per group. All animals are injected intravenously with 0.5 ml. 0.075% Bovine Serum Albumin (B.S.A.)+2% Evans Blue solution. Each rat then receives an oral dose of drug; one drug is administered per group.
- B.S.A. Bovine Serum Albumin
- each animal is injected intradermally with 0.05 ml. 1.44% Anti-B.S.A. into the dorsal skin.
- the animals are sacrificed, the dorsal skin reflexed, and the lesion excised. Two perpendicular diameters of each lesion are measured. The average diameters of the lesions from the treated groups are compared with the average diameters from the control group to determine any drug effect.
- Table II shows the percentage of reduction in lesion area produced by several representative compounds.
Abstract
Described are compounds of the formula ##STR1## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR2## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR3## and with the further provisos that at least four of the substituents R2 -R8 are hydrogen and R2 cannot be ##STR4## when R3 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
The compounds are effective as antiinflammatory and antiasthma agents.
Description
The present invention provides compositions for the treatment of rheumatoid arthritis, type III hypersensitivity diseases, diseases in which polymorphonuclear leukocyte accumulation contributes to the pathology, and other inflammatory conditions. An anti-inflammatory composition in dosage unit form is described.
The present invention is directed to compounds of the formula ##STR5## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR6## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR7## and with the further provisos that at least four of the substituents R2 -R8 are hydrogen and R2 cannot be ##STR8## when R3 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
The terms "loweralkyl" and "alkyl" as used herein refer to straight or branched chain alkyl radicals containing from 1 to 6 carbon atoms including but not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, 2-methylhexyl, n-pentyl, 1-methylbutyl, 2,2-dimethylbutyl, 2-methylpentyl, 2,2-dimethylpropyl, n-hexyl and the like.
The term "halo" as used herein refers to chloro, bromo, fluoro and iodo.
The compounds described in this invention are prepared by the reaction of the appropriate hydrazine quinolines with acrylonitrile in the presence of a base such as sodium methoxide, sodium ethoxide or sodium hydroxide, in a protic solvent such as a lower alcohol at a temperature of from about 50°-200° C. The reaction can also be carried out without any solvent at elevated temperatures of from about 50°-150° C. in the presence of an ammonium quatenary salt such as choline.
The term "pharmaceutically acceptable salts" includes nontoxic acid addition salts of the compounds of the invention which are generally prepared by reacting the free base with a suitable organic or inorganic acid. Representative salts include the hydrochloride, hydrobromide, sulfate, bisulfate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, and like salts. Also included are metallic salts such as the sodium or potassium salt of the acid.
The present compounds may be administered to warm-blooded animals orally or parenterally. They can generally be administered with a pharmaceutical carrier. The term "pharmaceutical carrier," for the purpose of the present invention, is intended to refer to any medium that is suitable for the preparation of a dosage unit form, and thus includes the tablet medium or a pharmaceutically acceptable vehicle or solvent such as is ordinarily used in the preparation of intravenous or intramuscular solutions.
A pharmaceutical composition containing the compound can be administered to warm-blooded animals in parenteral or oral dosage form. For oral administration, amounts of from about 0.1 to 200 mg./kg. per day per patient are useful, with the total dose of up to 0.5 to 5.0 gm. per day being a suitable range for large animals, including humans.
For all dosage forms, the above exemplified compounds can be placed in capsules, formulated into pills, wafers or tablets in conventional fashion together with pharmaceutical carriers well known in the art. Tablets may be prepared for immediate release of the active compound or they may be made enteric, i.e., whereby the active ingredient is released slowly over a period of several hours from within the intestinal tract.
In order to illustrate the manner in which the above compounds may be prepared and the properties of the compounds, reference is made to the following examples, which, however, are not meant to limit or restrict the scope of the invention in any respect.
To a solution of sodium ethoxide, prepared by dissolving sodium (2.78 g.) in ethanol (150 ml.), was added under nitrogen and with stirring 3-hydrazinoquinoline hydrochloride (12.5 g.). Then dropwise was added acrylonitrile (3.3 g.). The mixture was refluxed overnight and then concentrated in vacuo to 30 ml. of volume. The product precipitated, filtered and crystallized from ethanol to give 1-(3'-quinolinyl)-3-iminopyrazolidine, m.p. 202°-204°.
When the following hydrazino quinolines were allowed to react with acrylonitrile as described in the procedure of Example 1, the following compounds were obtained:
______________________________________
Hydrazines Products
______________________________________
2-hydrazinoquinoline
1-(2'-quinolinyl)-3-imino-
pyrazolidine;
m.p. 208-210° C.
4-hydrazino-7-chloroquinoline
1-(7'-chloro-4'-quino-
linyl)-3-imino pyrazo-
lidine; m.p. 205-207° C.
4-hydrazinoquinoline
1-(4'-quinolinyl)-3-imino-
pyrazolidine
5-hydrazinoquinoline
1-(5'-quinolinyl)-3-imino-
pyrazolidine m.p. 240-243° C.
6-hydrazinoquinoline
1-(6'-quinolinyl)-3-imino-
pyrazolidine
7-hydrazinoquinoline
1-(7'-quinolinyl)-3-imino-
pyrazolidine
8-hydrazinoquinoline
1-(8'-quinolinyl)-3-imino-
pyrazolidine, m.p. 184-186° C.
______________________________________
A stirred slurry of 2-amino-4-phenylquinoline (22 g.) in concentrated hydrochloric acid (50 ml.) was treated dropwise at 0° C. or below with sodium nitrite (7.0 g.) in cold water (35 ml.). The mixture was stirred for 0.5 hours at about 0° C. Stannous chloride dihydrate (56.7 g.) in cold concentrated hydrochloric acid (70 ml.) was added at 0° C. dropwise. The slurry was refrigerated overnight, filtered, and the precipitate was washed with saturated sodium chloride. The filtered solid was treated with excess concentrated sodium hydroxide solution and the hydrazine was extracted into ethyl acetate. The organic extract was washed, dried, decolorized and saturated with dry hydrogen chloride. On removal of the solvent, 2-hydrazino-4-phenylquinoline dihydrochloride was obtained. This compound was reacted with acrylonitrile using the same procedure described in Example 1.
When the following aminoquinolines are subjected to the same reaction conditions described in Example 3, the following compounds are obtained:
______________________________________
Aminoquinolines Products
______________________________________
4,6-dimethyl-8-aminoquinoline
1-(4',6'-dimethyl-8'-
quinolinyl)-3-imino-
pyrazolidine
6-methoxy-8-aminoquinoline
1-(6'-methoxy-8'-quino-
linyl)-3-iminopyra-
zolidine
6-bromo-8-aminoquinoline
1-(6'-bromo-8'-quino-
linyl)3-iminopyra-
zolidine
3-amino-6-methylquinoline
1-(6'-methyl-3'-quino-
linyl)3-iminopyra-
zolidine
3-amino-2-methylquinoline
1-(2'-methyl-3'-quino-
linyl)3-iminopyra-
zolidine
3-amino-4-methyl-6-chloroquinoline
1-(4'-methyl-6'-chloro-
3'-quinolinyl)-3-
iminopyrazolidine
2-methyl-4-aminoquinoline
1-(2'-methyl-4'-quino-
linyl)-3-iminopyra-
zolidine
2-amino-4-methylquinoline
1-(4'-methyl-2'-quino-
linyl)-3-iminopyra-
zolidine
4-phenyl-6-methoxy-8-aminoquinoline
1-(4'-phenyl-6'-meth-
oxy-8'-quinolinyl)-
3-iminopyrazolidine
2-phenyl-4-hydroxy-6-aminoquinoline
1-(2'-phenyl-4'-
hydroxy-6'-quino-
linyl)-3-iminopyra-
zolidine
6-chloro-8-aminoquinoline
1-(6'-chloro-8'-quino-
linyl)-3-amino-
pyrazolidine
8-chloro-5-aminoquinoline
1-(8'-chloro-5'-quino-
linyl)-3-iminopyra-
zolidine
7-chloro-6-aminoquinoline
1-(7'-chloro-5'-quino-
linyl)-3-iminopyra-
zolidine
______________________________________
A mixture of 4-chloro-7-trifluoromethylquinoline (21.95 g.) in ethanol (100 ml.) and hydrazine hydrate (60 g.) was refluxed overnight. The solvent and the excess of reagent were removed in vacuo to give 4-hydrazino-7-trifluoromethylquinoline hydrochloride.
The hydrazinoquinoline was reacted with acrylonitrile using the same conditions described in Example 1 to give 1-(7'-trifluoromethyl-4'-quinolyl)-3-iminopyrazolidine.
When the following chloroquinolines are subjected to the same reaction conditions described in Example 5, the following compounds are obtained:
______________________________________
Chloroquinolines Products
______________________________________
2-chloro-6-methoxyquinoline
1-(6'-methoxy-2'-quinolinyl)-
3-iminopyrazolidine
4-chloro-6-methylquinoline
1-(6'-methyl-4'-quinolinyl)-
3-iminopyrazolidine
4-chloro-8-methoxyquinoline
1-(8'-methoxy-4'-quinolinyl)-
3-iminopyrazolidine
4-chloro-8-methylquinoline
1-(8'-methyl-4'-quinolinyl)-
3-iminopyrazolidine
______________________________________
A suspension of 1-(3'-quinolinyl)-3-iminopyrazolidine (3 g.) in concentrated sulfuric acid (5 ml.) and water (50 ml.) was refluxed for 5 hours. The mixture was basified with concentrated ammonium hydroxide at 0° C. The precipitate was washed with water to give 1-(3'-quinolinyl)-3-pyrazolidinone.
When the following quinolinyl iminopyrazolidines were subjected to the same reaction conditions described in Example 7, the following compounds were obtained:
______________________________________
Quinolinyl-3-
iminopyrazolidines
Products
______________________________________
1-(2'-quinolinyl)-3-
1-(2'-quinolinyl)-3-pyra-
iminopyrazolidine
zolidinone
1-(7-chloro-4'- 1-(7'-chloro-4'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(4'-quinolinyl)-3-
1-(4'-quinolinyl)-3-
iminopyrazolidine
pyrazolidinone
1-(5'-quinolinyl)-3-
1-(5'-quinolinyl)-3-
iminopyrazolidine
pyrazolidinone
1-(6'-quinolinyl-3-
1-(6'-quinolinyl)-3-
iminopyrazolidine
pyrazolidinone
1-(7'-quinolinyl)-3-
1-(7'-quinolinyl)-3-
iminopyrazolidine
pyrazolidinone
1-(8'-quinolinyl)-3-
1-(8'-quinolinyl)-3-
iminopyrazolidine
pyrazolidinone
1-(4'-phenyl-2'- 1-(4'-phenyl-2'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(4',6'-dimethyl-8'-
1-(4',6'-dimethyl-8'-quino-
quinolinyl)-3- linyl)-3-pyrazolidinone
iminopyrazolidine
1-(6'-methoxy-8'-
1-(6'-methoxy-8'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(6'-bromo-8'- 1-(6'-bromo-8'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(6'-methyl-3'- 1-(6'-methyl-3'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(4'-methyl-6'-chloro-
1-(4'-methyl-6'-chloro-3'-
3'-quinolinyl)-3-
quinolinyl)-3-pyrazolidinone
iminopyrazolidine
1-(2'-methyl-4'- 1-(2'-methyl-4'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(4'-methyl-2'- 1-(4'-methyl-2'-quinolinyl)-
quinolinyl)-3- 3-pyrazolidinone
iminopyrazolidine
1-(4'-phenyl-6'- 1-(4'-phenyl-6'-methoxy-8'-
methoxy-8'- quinolinyl)-3-pyrazolidinone
quinolinyl)-3-
iminopyrazolidine
1-(2'-phenyl-4'-hydroxy-
1-(2'-phenyl-4'-hydroxy-6'-
6'-quinolinyl)-3-
quinolinyl)-3-pyrazolidinone
iminopyrazolidine
1-(7' -trifluoromethyl-
1-(7'-trifluoromethyl-4'-
4'-quinolinyl)-3-
quinolinyl)-3-pyrazolidinone
iminopyrazolidine
______________________________________
The compounds of the present invention have anti-inflammatory activity and inhibitory effect against Type III hypersensitivity reaction. These compounds are useful for the therapy of rheumatoid arthritis, other inflammatory conditions, Type III hypersensitivity diseases and in diseases in which polymorphonuclear leukocytes accumulation contributes to the pathology. The anti-inflammatory activity of these compounds was established by using a modification of the carrageenin pleurisy assay described by Vinegar et al. Proc. Soc. Exp. Biol. Med. 143:711 (1973). Table I shows the reduction in accumulation of exudate volume and leukocytes.
TABLE I
______________________________________
% Inhibition
Compound Dose Volume exudates Cells
______________________________________
Phenylbutazone 100 59 13
1-(3'-quinolinyl)-
60 86 71
3-iminopyrazolidine
______________________________________
The ability of these compounds to inhibit Type III hypersensitivity reactions was demonstrated using the reverse passive Arthus assay as described by Carter and Krause Fed. Proc. 35, 774 (1976). Each compound was administered orally to a group of four animals.
The Arthus reaction represents one of the oldest and best studied models of immunological injury. It is produced by the injection of antigen locally into a hyperimmunized animal or by the injection of a small amount of antibody into the skin of an animal that has just previously been given a large amount of soluble antigen intravenously. In both cases the antigen and antibody become deposited in the walls of small venules. Plasma complement is rapidly bound and activated. Within a few hours neutrophils (PMNs) accumulate resulting in disruption of the basement membrane of vessel walls and marked edema and hemorrage in the surrounding tissue.
Although the etiology of rheumatoid arthritis remains obscure, it is almost certain that immunological mechanisms play an important role in the pathogenesis of this disease. Therefore, inflammation induced by immunological reactions, which are believed to be important in the inflammatory processes of rheumatoid arthritis, make particularly desirable tools for the screening of potential anti-inflammatory agents. The usefulness of such a model depends upon how closely it represents the underlying pathological mechanisms of rheumatoid arthritis.
Based upon currently available evidence, a plausible sequence of events leading to the joint leisions in rheumatoid arthritis can be constructed. An initiating antigen, perhaps a transient synovial infection, results in an immune response and retention of the antigen within the joint structure. The interaction of antigen with developing antibodies results in the deposition of immune complexes. These complexes may fix and activate complement, causing the generation of a number of phlogistic and chemotactic substances. Phagocytosis of the complexes by attracted polymorphonuclear leukocytes (PMNs) leads to the release of lysosomal constituents. The enzymes released from lysosomes can erode articular cartilage and produce inflammation in the joint. The striking resemblance of these events to the Arthus phenomenon point to the utility of the Arthus reaction as a screen for anti-inflammatory compounds.
The reserve passive Arthus reaction test in rats is conducted as follows: Male Sprague-Dawley rats weighing approximately 130-160 g. are used, 4 rats per group. All animals are injected intravenously with 0.5 ml. 0.075% Bovine Serum Albumin (B.S.A.)+2% Evans Blue solution. Each rat then receives an oral dose of drug; one drug is administered per group.
Thirty minutes subsequent to drug dosing, each animal is injected intradermally with 0.05 ml. 1.44% Anti-B.S.A. into the dorsal skin. Four hours later the animals are sacrificed, the dorsal skin reflexed, and the lesion excised. Two perpendicular diameters of each lesion are measured. The average diameters of the lesions from the treated groups are compared with the average diameters from the control group to determine any drug effect.
Table II shows the percentage of reduction in lesion area produced by several representative compounds.
TABLE II
______________________________________
Dose % Inhibition of lesion
Compound mg/kg of dermal Arthus reaction
______________________________________
1-(3'-quinolinyl)-3-
100 37
iminopyrazolidine
1-(2'-quinolinyl)-3-
100 72
iminopyrazolidine
1-(7'-chloro-4'-
100 53
quinolinyl)-3-
iminopyrazolidine
______________________________________
Claims (38)
1. A compound of the formula ##STR9## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR10## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR11## and with the further proviso that at least four of the substituents R2 -R8 are hydrogen and, R2 cannot be ##STR12## when R3 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
2. A compound of the formula ##STR13## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, or ##STR14## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR15## and with the further proviso that at least four of the substituents R2 -R8 are hydrogen and, R2 cannot be ##STR16## when R3 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
3. A compound of the formula ##STR17## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, or ##STR18## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR19## and with the further proviso that at least four of the substituents R2 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
4. A compound of claim 2 wherein R2 is hydrogen or loweralkyl, R3 hydrogen or 3-amino-2-pyrazolinyl, R4 is hydrogen or 3-amino-2-pyrazolinyl, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-2-pyrazolinyl, R7 is hydrogen, halo or 3-amino-2-pyrazolinyl and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
5. A compound of claim 4 wherein R2 is hydrogen or methyl, R5 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen, chloro or 3-amino-2-pyrazolinyl and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
6. A compound of claim 4 wherein R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-2-pyrazolinyl, R7 is hydrogen or halo, and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
7. A compound of claim 6 wherein R5 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen or chloro, and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
8. A compound of claim 4 wherein R2 and R3 are hydrogen, R4 is 3-amino-2-pyrazolinyl, R5 and R6 are hydrogen, R7 is chloro, and R8 is hydrogen.
9. A compound of claim 4 wherein R2, R3 and R4 are hydrogen, R5 is 3-amino-2-pyrazolinyl, and R6, R7 and R8 are hydrogen.
10. A compound of claim 4 wherein R2 is hydrogen, R3 is 3-amino-2-pyrazolinyl, and R4, R5, R6, R7 and R8 are hydrogen.
11. A compound of claim 4 wherein R2 is methyl, R3 is hydrogen, R4 is 3-amino-2-pyrazolinyl, and R5, R6 R7 and R8 are hydrogen.
12. A compound of claim 4 wherein R2, R3, R4 and R5 are hydrogen, R6 is chloro, R7 is hydrogen and R8 is 3-amino-2-pyrazolinyl.
13. A compound of claim 4 wherein R2, R3, R4, R5, R6 and R7 are hydrogen and R8 is 3-amino-2-pyrazolinyl.
14. A compound of claim 4 wherein R2, R3 and R4 are hydrogen, R5 is 3-amino-2-pyrazolinyl, R6 and R7 are hydrogen, and R8 is chloro.
15. A compound of claim 4 wherein R2, R3, R4, R5, and R6 are hydrogen, R7 is 3-amino-2-pyrazolinyl, and R8 is hydrogen.
16. A compound of claim 4 wherein R2, R3, R4 and R5 are hydrogen, R6 is 3-amino-2-pyrazolinyl, R7 is chloro and R8 is hydrogen.
17. A compound of claim 4 wherein R2, R3, R4 and R5 are hydrogen, R6 is 3-amino-2-pyrazolinyl, and R7 and R8 are hydrogen.
18. A compound of claim 4 wherein R2, R3 and R4 are hydrogen, R5 is chloro, R6 is 3-amino-2-pyrazolinyl and R7 and R8 are hydrogen.
19. A compound of claim 3 wherein R2, R3, R4 are hydrogen, R5 is 3-keto-1-pyrazolidinyl, R6 is hydrogen, R7 is hydrogen and R8 is hydrogen.
20. A compound of claim 3 wherein R2, R3, R4 and R5 are hydrogen, R6 is 3-keto-1-pyrazolidinyl, and R7 and R8 are hydrogen.
21. A compound of claim 3 wherein R2 is hydrogen, R3 is 3-keto-1-pyrazolidinyl, and R4, R5, R6, R7 and R8 are hydrogen.
22. A compound of claim 3 wherein R2 is hydrogen, R3 is hydrogen, R4 is 3-keto-1-pyrazolidinyl, and R5, R6, R7 and R8 are hydrogen.
23. A method of treating or relieving the symptoms associated with inflammation comprising administering to a patient in need of such treatment a therapeutically effective amount of an antiinflammatory agent of the formula ##STR20## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR21## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR22## and with the further proviso that at least four of the substituents R2 -R8 are hydrogen, and pharmaceutically acceptable salts thereof.
24. The method of claim 23 wherein R2 is hydrogen or loweralkyl, R3 is hydrogen or 3-amino-2-pyrazolinyl, R4 is hydrogen or 3-amino-2-pyrazolinyl, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-2-pyrazolinyl, R7 is hydrogen, halo or 3-amino-2-pyrazolinyl and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
25. The method of claim 24 wherein R2 is hydrogen or methyl, R5 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen, chloro or 3-amino-2-pyrazolinyl and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
26. The method of claim 23 wherein R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-2-pyrazolinyl, R7 is hydrogen or halo, and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
27. The method of claim 26 wherein R5 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen or chloro and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
28. The method of claim 23 wherein R2, R3, R4, R5, R6 and R7 are hydrogen and R8 is 3-amino-2-pyrazolinyl.
29. The method of claim 23 wherein R2, R3 and R4 are hydrogen, R5 is 3-amino-2-pyrazolinyl, R6 and R7 are hydrogen, and R8 is chloro.
30. The method of claim 23 wherein R2, R3, R4, R5 and R6 are hydrogen, R7 is 3-amino-2-pyrazolinyl, and R8 is hydrogen.
31. The method of claim 23 wherein R2, R3, R4 and R5 are hydrogen, R6 is 3-amino-2-pyrazolinyl, R7 is chloro and R8 is hydrogen.
32. The method of claim 23 wherein R2, R3, R4 and R5 are hydrogen, R6 is 3-amino-2-pyrazolinyl and R7 and R8 are hydrogen.
33. The method of claim 23 wherein R2, R3 and R4 are hydrogen, R5 is chloro, R6 is 3-amino-2-pyrazolinyl and R7 and R8 are hydrogen.
34. A pharmaceutical composition useful for the treatment of inflammatory conditions which comprises a compound of the formula ##STR23## wherein R2 -R8 independently of one another denote hydrogen, loweralkyl, phenyl, alkoxy, halo, hydroxy, nitro, trifluoromethyl, ##STR24## with the proviso that at least one but no more than one of the substituents R2 -R8 is ##STR25## and with the further proviso that at least four of the substituents R2 -R8 are hydrogen and pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
35. The composition of claim 34 wherein R2 is hydrogen or loweralkyl, R3 is hydrogen or 3-amino-2-pyrazolinyl, R4 is hydrogen or 3-amino-2-pyrazolinyl, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-pyrazolinyl, R7 is hydrogen, halo or 3-amino-2-pyrazolinyl and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
36. The composition fo claim 35 wherein R2 is hydrogen, or methyl, R5 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen, chloro or 3-amino-2-pyrazolinyl and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
37. The composition of claim 34 wherein R2 is hydrogen, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, halo or 3-amino-2-pyrazolinyl, R6 is hydrogen, halo or 3-amino-2-pyrazolinyl, R7 is hydrogen or halo and R8 is hydrogen, halo or 3-amino-2-pyrazolinyl.
38. The composition of claim 37 wherein R2 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R6 is hydrogen, chloro or 3-amino-2-pyrazolinyl, R7 is hydrogen or chloro and R8 is hydrogen, chloro or 3-amino-2-pyrazolinyl.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/293,767 US4407803A (en) | 1981-08-17 | 1981-08-17 | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US06/293,767 US4407803A (en) | 1981-08-17 | 1981-08-17 | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| US4407803A true US4407803A (en) | 1983-10-04 |
Family
ID=23130495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US06/293,767 Expired - Fee Related US4407803A (en) | 1981-08-17 | 1981-08-17 | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives |
Country Status (1)
| Country | Link |
|---|---|
| US (1) | US4407803A (en) |
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4968701A (en) * | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
| US5051427A (en) * | 1987-11-03 | 1991-09-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline derivatives as antagonists of leukotriene D4 |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| EP0784052A1 (en) * | 1988-06-21 | 1997-07-16 | Rhone-Poulenc Rorer International (Holdings) Inc. | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation |
| US6376519B1 (en) | 1999-06-16 | 2002-04-23 | Temple University-Of The Commonwealth Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| US20050131014A1 (en) * | 2003-12-12 | 2005-06-16 | Wyeth | Quinolines useful in treating cardiovascular disease |
| WO2015058021A1 (en) * | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9024031B1 (en) | 2014-08-19 | 2015-05-05 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9029554B1 (en) | 2013-10-17 | 2015-05-12 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9029556B1 (en) | 2014-07-31 | 2015-05-12 | Dow Argosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9029555B1 (en) | 2014-07-31 | 2015-05-12 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9044017B2 (en) | 2013-10-17 | 2015-06-02 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9085564B2 (en) | 2013-10-17 | 2015-07-21 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9085552B1 (en) | 2014-09-12 | 2015-07-21 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9102655B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9174962B2 (en) | 2013-10-17 | 2015-11-03 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9199964B1 (en) | 2014-07-31 | 2015-12-01 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9255083B2 (en) | 2013-10-17 | 2016-02-09 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA484853A (en) * | 1952-07-15 | Weissberger Arnold | Heterocyclic substituted amino pyrazolones | |
| US3169966A (en) * | 1961-01-24 | 1965-02-16 | Ciba Geigy Corp | Aminopyrazoles |
| US3996231A (en) * | 1973-07-13 | 1976-12-07 | Choay S.A. | 1-Quinolinyl-pyrazolidine derivatives |
| US4226773A (en) * | 1979-05-07 | 1980-10-07 | Abbott Laboratories | Pyrazolyl amino imidazolines as diuretic agents |
-
1981
- 1981-08-17 US US06/293,767 patent/US4407803A/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA484853A (en) * | 1952-07-15 | Weissberger Arnold | Heterocyclic substituted amino pyrazolones | |
| US3169966A (en) * | 1961-01-24 | 1965-02-16 | Ciba Geigy Corp | Aminopyrazoles |
| US3996231A (en) * | 1973-07-13 | 1976-12-07 | Choay S.A. | 1-Quinolinyl-pyrazolidine derivatives |
| US4226773A (en) * | 1979-05-07 | 1980-10-07 | Abbott Laboratories | Pyrazolyl amino imidazolines as diuretic agents |
Non-Patent Citations (1)
| Title |
|---|
| Finar, et al., Chemical Abstracts, vol. 53, 7173d (1959). * |
Cited By (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5051427A (en) * | 1987-11-03 | 1991-09-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Quinoline derivatives as antagonists of leukotriene D4 |
| US4968701A (en) * | 1988-04-26 | 1990-11-06 | E. I. Du Pont De Nemours And Company | 4-Quinoline carboxylic acid derivatives useful as immunosuppressive agents |
| EP0784052A1 (en) * | 1988-06-21 | 1997-07-16 | Rhone-Poulenc Rorer International (Holdings) Inc. | Quinoline derivatives as antagonists of leukotriene d4, compositions containing the same and processes for their preparation |
| US5204329A (en) * | 1990-06-11 | 1993-04-20 | Du Pont Merck Pharmaceutical Company | Treatment of organ transplantation rejection |
| US6376519B1 (en) | 1999-06-16 | 2002-04-23 | Temple University-Of The Commonwealth Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| USRE39681E1 (en) | 1999-06-16 | 2007-06-05 | Temple University - Of The Commonwealth System Of Higher Education | 1-(4-sulfamyaryl)-3-substituted-5-aryl-2-pyrazolines and inhibitors of cyclooxygenase-2 |
| US20050131014A1 (en) * | 2003-12-12 | 2005-06-16 | Wyeth | Quinolines useful in treating cardiovascular disease |
| US7576215B2 (en) | 2003-12-12 | 2009-08-18 | Wyeth | Quinolines and pharmaceutical compositions thereof |
| US9126974B2 (en) | 2013-10-17 | 2015-09-08 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9670164B2 (en) | 2013-10-17 | 2017-06-06 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9029554B1 (en) | 2013-10-17 | 2015-05-12 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9988356B2 (en) | 2013-10-17 | 2018-06-05 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9908864B2 (en) | 2013-10-17 | 2018-03-06 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9044017B2 (en) | 2013-10-17 | 2015-06-02 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9085564B2 (en) | 2013-10-17 | 2015-07-21 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9901095B2 (en) | 2013-10-17 | 2018-02-27 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9102655B2 (en) | 2013-10-17 | 2015-08-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9862702B2 (en) | 2013-10-17 | 2018-01-09 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9434712B2 (en) | 2013-10-17 | 2016-09-06 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9796682B2 (en) | 2013-10-17 | 2017-10-24 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9174962B2 (en) | 2013-10-17 | 2015-11-03 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9723839B2 (en) | 2013-10-17 | 2017-08-08 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9199942B2 (en) | 2013-10-17 | 2015-12-01 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US10315999B2 (en) | 2013-10-17 | 2019-06-11 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9670178B2 (en) | 2013-10-17 | 2017-06-06 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9661849B2 (en) | 2013-10-17 | 2017-05-30 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| WO2015058021A1 (en) * | 2013-10-17 | 2015-04-23 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9255082B2 (en) | 2013-10-17 | 2016-02-09 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9580405B2 (en) | 2013-10-17 | 2017-02-28 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9255083B2 (en) | 2013-10-17 | 2016-02-09 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9260396B2 (en) | 2013-10-17 | 2016-02-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9550751B2 (en) | 2013-10-17 | 2017-01-24 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| CN105636440A (en) * | 2013-10-17 | 2016-06-01 | 美国陶氏益农公司 | Processes for the preparation of pesticidal compounds |
| US9540342B2 (en) | 2013-10-17 | 2017-01-10 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9414594B2 (en) | 2013-10-17 | 2016-08-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9447048B2 (en) | 2013-10-17 | 2016-09-20 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9433215B2 (en) | 2013-10-17 | 2016-09-06 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US9611247B2 (en) | 2014-07-31 | 2017-04-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9249122B1 (en) | 2014-07-31 | 2016-02-02 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US10035786B2 (en) | 2014-07-31 | 2018-07-31 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US9371310B2 (en) | 2014-07-31 | 2016-06-21 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9029556B1 (en) | 2014-07-31 | 2015-05-12 | Dow Argosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9573931B2 (en) | 2014-07-31 | 2017-02-21 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9580403B2 (en) | 2014-07-31 | 2017-02-28 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9255081B1 (en) | 2014-07-31 | 2016-02-09 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| CN106470976A (en) * | 2014-07-31 | 2017-03-01 | 美国陶氏益农公司 | The method of preparation 3 (3 chlorine 1H pyrazoles 1 base) pyridine |
| CN106488908A (en) * | 2014-07-31 | 2017-03-08 | 美国陶氏益农公司 | The method for preparing 3 (3 chlorine 1H pyrazoles, 1 base) pyridine |
| CN106488909A (en) * | 2014-07-31 | 2017-03-08 | 美国陶氏益农公司 | The method for preparing 3 (3 chlorine 1H pyrazoles, 1 base) pyridine |
| WO2016018442A1 (en) * | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US9029555B1 (en) | 2014-07-31 | 2015-05-12 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| WO2016018443A1 (en) * | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| WO2016018444A1 (en) * | 2014-07-31 | 2016-02-04 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US9840490B2 (en) | 2014-07-31 | 2017-12-12 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9199964B1 (en) | 2014-07-31 | 2015-12-01 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9522900B2 (en) | 2014-08-19 | 2016-12-20 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9809570B2 (en) | 2014-08-19 | 2017-11-07 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9115115B1 (en) | 2014-08-19 | 2015-08-25 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US10005758B2 (en) | 2014-08-19 | 2018-06-26 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9024031B1 (en) | 2014-08-19 | 2015-05-05 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9422265B2 (en) | 2014-09-12 | 2016-08-23 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9896430B2 (en) | 2014-09-12 | 2018-02-20 | Dow Agrosciences Llc | Process for the preparation of 3-(3-CHLORO-1H-pyrazol-1-yl)pyridine |
| US9085552B1 (en) | 2014-09-12 | 2015-07-21 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US9663489B2 (en) | 2014-09-12 | 2017-05-30 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| WO2016039781A1 (en) * | 2014-09-12 | 2016-03-17 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1h-pyrazol-1-yl)pyridine |
| US9156813B1 (en) | 2014-09-12 | 2015-10-13 | Dow Agrosciences Llc | Process for the preparation of 3-(3-chloro-1H-pyrazol-1-yl)pyridine |
| US10100033B2 (en) | 2016-12-29 | 2018-10-16 | Dow Agrosciences Llc | Processes for the preparation of pesticidal compounds |
| US10233155B2 (en) | 2016-12-29 | 2019-03-19 | Dow Agrosciences Llc | Processes for the preparation of pesticide compounds |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4407803A (en) | Antiinflammatory 1-(quinolinyl)-2-pyrazoline derivatives | |
| US4340598A (en) | Hypotensive imidazole derivatives | |
| EP0091468B1 (en) | (1-(2-benzoxazolyl)hydrazino)alkyl nitrile derivatives | |
| US4351841A (en) | Pharmaceutical preparation and method of treatment | |
| SK178598A3 (en) | Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators | |
| JPS63225340A (en) | Lipoxygenase inhibition compound | |
| JPS6229566A (en) | Novel guanidinomthylbenzoic acid derivative | |
| US4590205A (en) | Antiinflammatory and/or analgesic 2,3-diaryl-5-halo thiophenes | |
| GB1580110A (en) | Substituted tetrazole compounds | |
| JPH0153266B2 (en) | ||
| US4285943A (en) | Novel pharmaceutical compositions incorporating an aryltrifluoroethanol | |
| PL103682B1 (en) | METHOD OF MAKING NEW DERIVATIVES OF INDAZOLYLOXY-4-PROPANOLOAMINE | |
| US4342769A (en) | 2-[(Methylsulfinyl)acetyl]-3-heterocyclicindoles and derivatives thereof as immunosuppressants | |
| US4053621A (en) | 1-[2-(βNaphthyloxy)ethyl]-3-methylpyrazolone-(5) and antithrombotic and antithrombolytic compositions and methods utilizing them | |
| US4503056A (en) | 1-(Pyridazinyl)pyrazoline derivatives | |
| US4171367A (en) | Pyrazolyl amino imidazolines | |
| TW445261B (en) | A substituted thiophenylalkenylcarboxylic acid guanidide compound having the cellular Na<SP>+</SP>/H<SP>+</SP> exchanger inhibitory activity, the preparation processes and the pharmaceutical compositions thereof | |
| US4370339A (en) | Method for treating inflammatory conditions | |
| US4333951A (en) | 2-Amino-6-biphenylacetic acids | |
| US3595876A (en) | Spiro-azatetramethylene derivatives | |
| JPH02502534A (en) | Tromethamine salt of 1-methyl-β-oxo-α-(phenylcarbamoyl)-2-pyrrolepropionitrile | |
| US4259335A (en) | 1-Methyl-4-piperidinol esters of 4-quinolinylamino benzoates and antiinflammatory and analgesic compositions and methods employing them | |
| US3420839A (en) | Aminomethyl pyrazolone derivatives of nicotinamide | |
| US4489084A (en) | [1-(2-Oxazolyl) or -(2-thiazolyl) hydrazino]alkyl nitriles | |
| US4681884A (en) | Diazine-ethenylphenyl oxamic acids and esters and salts thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AS | Assignment |
Owner name: ABBOTT LABORATORIES, CHICAGO, ILL., A CORP. OF ILL Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:HAVIV, FORTUNA;DENET, ROBERT W.;REEL/FRAME:004142/0836 Effective date: 19810812 |
|
| MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YEAR, PL 96-517 (ORIGINAL EVENT CODE: M170); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY Year of fee payment: 4 |
|
| FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
| LAPS | Lapse for failure to pay maintenance fees | ||
| FP | Lapsed due to failure to pay maintenance fee |
Effective date: 19911006 |
|
| STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |